Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
OneSource Specialty Pharma Ltd, Adani Ports & Special Economic Zone Ltd, Graphite India Ltd, DLF Ltd are among the other stocks to see a surge in volumes on BSE today, 09 September 2026.
Biocon Ltd clocked volume of 168.67 lakh shares by 10:45 IST on BSE, a 75.68 times surge over two-week average daily volume of 2.23 lakh shares. The stock gained 1.55% to Rs.398.65. Volumes stood at 1.22 lakh shares in the last session.
OneSource Specialty Pharma Ltd saw volume of 6.91 lakh shares by 10:45 IST on BSE, a 34.12 fold spurt over two-week average daily volume of 20246 shares. The stock dropped 2.59% to Rs.1,545.05. Volumes stood at 86505 shares in the last session.
Adani Ports & Special Economic Zone Ltd witnessed volume of 60.3 lakh shares by 10:45 IST on BSE, a 21.52 times surge over two-week average daily volume of 2.80 lakh shares. The stock increased 2.75% to Rs.1,755.80. Volumes stood at 3.15 lakh shares in the last session.
Graphite India Ltd witnessed volume of 15.49 lakh shares by 10:45 IST on BSE, a 17.56 times surge over two-week average daily volume of 88204 shares. The stock increased 16.60% to Rs.856.40. Volumes stood at 56869 shares in the last session.
DLF Ltd witnessed volume of 33.45 lakh shares by 10:45 IST on BSE, a 15.02 times surge over two-week average daily volume of 2.23 lakh shares. The stock dropped 1.23% to Rs.667.65. Volumes stood at 9.14 lakh shares in the last session.
Sarda Energy & Minerals Ltd, OneSource Specialty Pharma Ltd, Mangalore Refinery And Petrochemicals Ltd, DLF Ltd are among the other stocks to see a surge in volumes on NSE today, 09 September 2026.
Graphite India Ltd clocked volume of 304.64 lakh shares by 14:14 IST on NSE, a 20.78 times surge over two-week average daily volume of 14.66 lakh shares. The stock gained 17.53% to Rs.862.95. Volumes stood at 12.09 lakh shares in the last session.
Sarda Energy & Minerals Ltd notched up volume of 42.38 lakh shares by 14:14 IST on NSE, a 12.4 fold spurt over two-week average daily volume of 3.42 lakh shares. The stock rose 6.17% to Rs.551.90. Volumes stood at 7.58 lakh shares in the last session.
OneSource Specialty Pharma Ltd saw volume of 21.82 lakh shares by 14:14 IST on NSE, a 11.34 fold spurt over two-week average daily volume of 1.92 lakh shares. The stock dropped 2.22% to Rs.1,544.40. Volumes stood at 7.07 lakh shares in the last session.
Mangalore Refinery And Petrochemicals Ltd clocked volume of 399.67 lakh shares by 14:14 IST on NSE, a 6.53 times surge over two-week average daily volume of 61.21 lakh shares. The stock gained 6.89% to Rs.184.88. Volumes stood at 51.81 lakh shares in the last session.
DLF Ltd registered volume of 150.22 lakh shares by 14:14 IST on NSE, a 6.16 fold spurt over two-week average daily volume of 24.39 lakh shares. The stock slipped 1.47% to Rs.665.20. Volumes stood at 24.26 lakh shares in the last session.
The rating on the short-term facilities has been reaffirmed at ‘IND A1’.
India Ratings and Research said that the upgrade reflects the strengthening of OSPL's business profile, following the successful commercialisation of its drug device combination (DOC) platform and increasing contribution from commercial glucagon-like peptide-1 (GLP-1) supplies.
India Ratings believes the company has transitioned from a predominantly development-led revenue model to an increasingly commercial supply-led model, supported by multiple customer launches, long-term supply agreements, and capacity expansion.
The demonstrated conversion of development projects into commercial supplies and the ramp-up of commercial revenue have improved its revenue visibility, strengthened customer stickiness, and reduced execution risk.
The ratings continue to benefit from OSPL's diversified contract development and manufacturing organisation (CDMO) platform across DDCs, biologics, sterile injectables and softgels; an established presence in regulated markets; and integrated manufacturing capabilities.
The agency has observed a significant improvement in the company’s scale of EBITDA during 4Q FY26 - 1Q FY27, led by the genericisation of GLP-1 portfolio in various markets.
India Ratings expects increasing utilisation of expanded capacities, growing CSA revenues, and improving operating leverage to support stronger profitability, cash flow generation and gradual deleveraging over the medium term.
Onesource Specialty Pharma is a fully integrated, multi-modality specialty pharmaceutical CDMO company, focused on developing and manufacturing drug-device combinations (DDCs), biologics, sterile injectables and oral technologies like soft gelatin capsules for its customers out of five globally compliant facilities located in Bengaluru.
The scrip shed 0.32% to currently trade at Rs 1546.95 on the BSE.
The company reported a profit before exceptional items and tax of Rs 24.59 crore during the quarter, compared with a loss before exceptional items and tax of Rs 1.52 crore in the year-ago period.
During the quarter, the company recorded an exceptional loss of Rs 4.30 crore on account of legal charges related to legacy litigation involving employees of a subsidiary.
EBITDA stood at Rs 123.3 crore, registering the growth of 39% YoY. EBITDA margin improved to 27.5% in Q1 FY27 as against 27% in Q1 FY26.
Looking ahead, the company reiterated its FY28 guidance, targeting $400 million in organic revenue and an EBITDA margin of 40%, reflecting confidence in its long-term growth trajectory.
Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said, “We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.”
OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules).
OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics' facility in Bangalore.
The collaboration brings together Formycon´s Biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.
The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.